To explore the clinical efficacy of albumin bound paclitaxel combined with Yiai Sanjie Decoction in the treatment of pancreatic cancer. Methods:A total of 66 cases of pancreatic cancer patients in our hospital from April 2013 to June 2017 were selected and divided randomly into control group and study group, with 33 cases in each group. Patients in control group were treated with GEM chemotherapy regimens combined with albumin bound paclitaxel, and patients in study group were treated with Yiai Sanjie Decoction on the basis of control group. 6 months after continuous treatment, the clinical efficacy and KPS scores in 2 groups were statisticsed; the serum tumor marks molecules before and after treatment in 2 groups were detected and compared; the occurrence of adverse reaction in 2 groups were compared during treatment. Results:The RR in study group 6 months after treatment was 75.76%, which was higher than that 51.52% in control group (P<0.05); the KPS score effective rate in study group 6 months after treatment was 87.88%, which was higher than that 66.67% in control group (P<0.05), and the KPS score in study group 6 months after treatment was also higher than that in control group (P<0.01); compared with before treatment, the serum CEA, CA125 and CA19-9 levels in 2 groups decreased after treatment, and study group was lower than control group (P<0.05); compared with control group, the proportion of patients with Ⅰ+Ⅱ class nausea and vomiting, aminotransferase on the high side and thrombocytopenia in study group decreased significantly (P<0.05). Conclusion:Albumin bound paclitaxel combined with Yiai Sanjie Decoction can reduce the serum tumor markers molecules content of pancreatic cancer patients, enhance the clinical efficacy significantly, and lessen the adverse reaction of chemotherapy, improve the patients' prognosis.